Abstracts tagged "Immunotherapy"

Abstract Number: 357 • 2018 ACR/ARHP Annual Meeting
Musculoskeletal Immune-Related Adverse Events with Use of Checkpoint Inhibitors in Malignancy: Experience in Sydney, Australia
Abhishikta Dey^1,2, Nicholas Manolios^3,4, Georgina Long^4,5,6, Richard Kefford^3,4,5,7 and Leslie Schrieber^8,9, ¹Pain Medicine, Royal Prince Alfred Hospital, Camperdown, Australia, ²Royal North Shore Hospital, North Sydney, Australia, ³Westmead Hospital, Sydney, Australia, ⁴University of Sydney, Sydney, Australia, ⁵Melanoma Institute Australia, North Sydney, Australia, ⁶Royal North Shore Hospital, St Leonards, Australia, ⁷Macquarie University Hospital, Sydney, Australia, ⁸Royal North Shore Hospital, St Leonards, Sydney, Australia, ⁹Northern Clinical School, University of Sydney, Sydney, Australia
Background/Purpose: The strategy of using monoclonal antibodies to inhibit checkpoints on T cells, and enhance T-cell activity against cancer cells has significantly improved the survival…
Abstract Number: 358 • 2018 ACR/ARHP Annual Meeting
Immunophenotypic Analysis of T Cells from Leukemia Patients with Immune Checkpoint Inhibitor-Associated Respiratory Complications
Sang Kim¹, Vickie Shannon², Ajay Sheshardi², Hagop Kantarjian³, Guillermo Garcia-Manero³, Farhad Ravandi³, Aung Naing⁴, Padmanee Sharma⁵, Jin Im⁶, Wilfredo Ruiz Vazquez⁶, Adi Diab⁷, Dimitrios Kontoyiannis⁸, Andrew Futreal⁹ and Naval Daver³, ¹General Internal Medicine, MD Anderson Cancer Center, Houston, TX, ²Pulmonary Medicine, MD Anderson Cancer Center, Houston, TX, ³Leukemia, MD Anderson Cancer Center, Houston, TX, ⁴Investigational Cancer Therapeutics, MD Anderson Cancer Center, Houston, TX, ⁵Genitourinary Medical Oncology, MD Anderson Cancer Center, Houston, TX, ⁶Stem Cell Transplantation, MD Anderson Cancer Center, Houston, TX, ⁷Melanoma Medical Oncology, Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, Houston, TX, ⁸Infectious Diseases, MD Anderson Cancer Center, Houston, TX, ⁹Genomic Medicine, MD Anderson Cancer Center, Houston, TX
Background/Purpose: Immune checkpoint inhibitor (ICI)-based combinations are showing encouraging results in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) treatment; however, ICIs can cause immune-related…
Abstract Number: 360 • 2018 ACR/ARHP Annual Meeting
Sarcoidosis Induced By Immune Check Point Inhibitors
Noémie Chanson¹, Pauline Pradère², Anne-Laure Voisin³, Stéphane Champiat⁴, Aurélien Marabelle⁴ and Olivier Lambotte⁵, ¹Internal Medicine, Hopital Bicetre, LE KREMLIN BICETRE, France, ²Hopital Marie Lannelongue, Le Plessis Robinson, France, ³Unité Fonctionnelle de Pharmacovigilance, Gustave Roussy Institut, Villejuif, France, ⁴Drug Development Department, Gustave Roussy Institut, Villejuif, France, ⁵Internal Medicine, Hopital Kremlin Bicêtre, Kremlin Bicêtre, France
Background/Purpose: Immune check point inhibitors (ICIs) targeting programmed cell death-1 (PD-1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) have demonstrated improved survival for multiple cancers…
Abstract Number: 361 • 2018 ACR/ARHP Annual Meeting
Risk Factors of Immune-Related Adverse Events in Patients Treated with Anti-Programmed Cell Death 1 Antibody Pembrolizumab
In Young Kim¹, Yeonghee Eun¹, Hyungjin Kim¹, Joong Kyong Ahn², Eun-Jung Park³, Chan Hong Jeon⁴, Jinseok Kim⁵, Hoon-Suk Cha¹, Eun-Mi Koh¹ and Jaejoon Lee¹, ¹Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South), ²Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South), ³Department of Medicine, National Medical Center, Seoul, Korea, Republic of (South), ⁴Department of Medicine, Soonchunhyang University College of Medicine, Bucheon, Korea, Republic of (South), ⁵Department of Medicine, Jeju National University Hospital, University of Jeju School of Medicine, Jeju, Korea, Republic of (South)
Background/Purpose: Immune checkpoint inhibitors have been established as a novel standard treatment for various types of malignancies. However, these new class of drugs have led…
Abstract Number: 364 • 2018 ACR/ARHP Annual Meeting
Elevated sCD40L As a Predictive Biomarker of Immune-Related Adverse Events in Patients Receiving Immune Checkpoint Inhibitors
Nicholas Meti¹, Khashayar Esfahani^1,2, Ines Colmegna^1,3, Marvin J. Fritzler⁴, Nathalie A. Johnson^1,5, Ciriaco Piccirillo^1,6, Wilson H. Miller Jr.^1,2 and Marie Hudson^1,7, ¹Department of Medicine, McGill University, Montreal, QC, Canada, ²Department of Oncology, McGill University, Jewish General Hospital, Rossy Cancer Network, Montreal, QC, Canada, ³Division of Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁴Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁵Division of Hematology, Jewish General Hospital, Montreal, QC, Canada, ⁶Department of Microbiology & Immunology, McGill University, Montreal, QC, Canada, ⁷Division of Rheumatology, Jewish General Hospital, Montreal, QC, Canada
Background/Purpose: The clinical use of immune checkpoint inhibitors (ICI) has led to outstanding clinical outcomes in previously refractory cancers, but ICI have also been associated…
Abstract Number: 701 • 2018 ACR/ARHP Annual Meeting
Network Meta-Analysis of Targeted Immunomodulators in the Treatment of Psoriatic Arthritis Patients without Prior Biologic Treatment
Vibeke Strand¹, M. Elaine Husni², Jenny Griffith³, Yan Song⁴, Rakesh Singh⁵, Jing Zhao⁶ and Keith A. Betts⁷, ¹Stanford University, Palo Alto, CA, ²Orthopedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH, ³AbbVie, Inc., North Chicago, IL, ⁴Analysis Group, Inc., Boston, MA, ⁵AbbVie Inc., North Chicago, IL, ⁶Analysis Group Inc, Boston, MA, ⁷Analysis Group, Inc., Los Angeles, CA
Background/Purpose: With multiple targeted immunomodulators (TIMs) approved by the FDA for the treatment of psoriatic arthritis (PsA), the relative efficacy and cost-effectiveness of these TIMs…
Abstract Number: 1723 • 2018 ACR/ARHP Annual Meeting
Intensified B-Cell Depletion Therapy in Progressive Systemic Sclerosis Patients: 24 Months Follow-up
Daniela Rossi¹, Irene Cecchi², Massimo Radin³, Elena Rubini⁴, Savino Sciascia⁵ and Dario Roccatello⁶, ¹Department of Medicine and Experimental Oncology, CMID - Center of Research of Immunopathology and Rare Diseases, Turin, Italy, ²Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ³Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁴Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy., Turin, Italy, ⁵Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy, ⁶Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy
Background/Purpose:Systemic sclerosis (SSc) is a connective tissue autoimmune disease with systemic involvement and a serious medical condition with a high rate of mortality, especially due…
Abstract Number: 2095 • 2018 ACR/ARHP Annual Meeting
Neutralizing CXCL13 Attenuates Neuropsychiatric Disease in Lupus-Prone Mice
Michelle Huang¹, Ariel Stock² and Chaim Putterman³, ¹Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Despite the many lupus patients affected by neuropsychiatric signs and symptoms, the pathogenesis of neuropsychiatric disease in SLE remains unclear. MRL-lpr/lpr mice, a classic…
Abstract Number: 2349 • 2018 ACR/ARHP Annual Meeting
“I Was Prepared for the Other Side Effects; I Wasn’t Prepared for This One.”: A Qualitative Study of the Patients’ Experience of Inflammatory Arthritis Due to Immune Checkpoint Inhibitor Therapy for Cancer
Laura C. Cappelli¹, Suzanne Grieb², Ana-Maria Orbai³, Ami A. Shah¹ and Clifton O. Bingham III⁴, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins Bayview Medical Center, Center for Child and Community Health Research, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Patients treated for cancer with immune checkpoint inhibitors (ICI) can develop a variety of adverse events. Inflammatory arthritis (IA) is an increasingly recognized event…
Abstract Number: 2683 • 2018 ACR/ARHP Annual Meeting
Selective Expansion and Targeting of FoxP3+CD127lo Regulatory T Cells By Low-Dose IL-2 Therapy in Active SLE
Jens Humrich¹, Caroline von Spee-Mayer², Philipp Enghard³, Angelika Rose⁴, Elise Siegert⁵, Tobias Alexander⁵, Falk Hiepe⁶, Gerd R. Burmester⁷ and Gabriela Riemekasten⁸, ¹Department of Rheumatology, University Hospital Schleswig-Holstein - Campus Lübeck, Lübeck, Germany, ²Immunology, University Hospital Freiburg, Freiburg, Germany, ³Department of Nephrology, Charité – University Medicine Berlin, Berlin, Germany, ⁴Rheumatology and Clinical Immunology, Charité – University Medicine Berlin, Berlin, Germany, ⁵Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, ⁶Rheumatology, Charité – University Medicine Berlin, Berlin, Germany, ⁷Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ⁸Rheumatology, University Hospital Schleswig-Holstein - Campus Lübeck, Lübeck, Germany
Background/Purpose: Interleukin-2 (IL-2) is crucial for the growth and survival of regulatory T cells (Treg), and thus for the control of autoimmunity. In previous studies…
Abstract Number: 346 • 2018 ACR/ARHP Annual Meeting
Immune-Related Adverse Events: Development of a Pilot Immune-Related Adverse Events Clinic for Expedited and Effective Patient Care
Pankti Reid¹ and Reem Jan², ¹Internal Medicine, rheumatology, University of Chicago, Chicago, IL, ²Medicine, Rheumatology, University of Chicago, Chicago, IL
Background/Purpose: The growing use of cancer immunotherapy and checkpoint inhibitors has led to a steep rise in immune-related adverse events (irAEs). Despite expanding research efforts,…
Abstract Number: 2976 • 2018 ACR/ARHP Annual Meeting
Immune Checkpoint Inhibitor-Associated Myositis: A Characteristic Phenotype with a Poor Outcome Related to Concomitant Myocarditis
Celine Anquetil^1,2, Joe-Elie Salem^3,4, Benedicte Lebrun-Vignes⁵, Douglas B Johnson⁶, Andrew Mammen^7,8, Werner Stenzel⁹, Sarah Leonard-louis¹⁰, Olivier Benveniste^11,12, Javid J Moslehi³ and Yves Allenbach^2,13, ¹Internal Medicine and Clinical Immunlogy, Assistance Public - Hopitaux de Paris, Pitié-Salpêtrière University Hospital, PARIS, France, ²CDR en myologie UMR974,, Institut National de la Santé et de la Recherche Médicale, Association Institut de Myologie, PARIS, France, ³Division of Cardiovascular Medicine and Cardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center, Nasheville, TN, ⁴Department of Pharmacology, Regional Center of Pharmacovigilance, INSERM, CIC-1421, Paris, France, ⁵Department of Pharmacology, Regional Center of Pharmacovigilance, INSERM, CIC-1421, PARIS, France, ⁶Division of Oncology, Department of Medicine, Vanderbilt University Medical Center, Nasheville, TN, ⁷National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁸Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁹Charité - Universitätsmedizin, Department of Neuropathology, Berlin, Germany, Berlin, Germany, ¹⁰Département de Neuropathologie, Centre de Référence des Maladies Neuro-Musculaires Paris Est, Assistance Publique – Hôpitaux de Paris (AP-HP), Hôpital Universitaire Pitié-Salpêtrière, Paris, France, ¹¹Department of Internal Medicine and Clinical Immunology and Inflammation-Immunopathology-Biotherapy Department (I2B), Pitié-Salpêtrière University Hospital, Assistance Publique-Hôpitaux de Paris, East Paris Neuromuscular Diseases Reference Center, Paris, France, ¹²Centre de Recherche en Myologie, UMRS974, Institut National de la Santé et de la Recherche Médicale, Association Institut de Myologie, Paris, France, ¹³Internal Medicine and Clinical Immunology, Sorbonne University - Assistance Public - Hopitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France
Background/Purpose: Immune checkpoint inhibitors (ICI) are a major breakthrough in cancer treatment providing frequent durable responses and improving overall survival. Blocking immune checkpoints (Programmed cell…
Abstract Number: 350 • 2018 ACR/ARHP Annual Meeting
Clinical Correlates of Immune-Related Adverse Events for Patients with Melanoma Treated with Checkpoint Inhibitors and a Noted Significant Difference in Peripheral Lymphocyte Counts
Pankti Reid¹, Tara Chongsuwat², Anisha Dua³ and Jason Luke⁴, ¹Internal Medicine, rheumatology, University of Chicago, Chicago, IL, ²Oncology Research Coordinator, University of Chicago, Chicago, IL, ³Medicine, University of Chicago, Chicago, IL, ⁴Hematology Oncology, University of Chicago, Chicago, IL
Background/Purpose: Checkpoint immunotherapy has become the standard of care in treating advanced melanoma. These medications have been associated with immune-related adverse events (irAEs). Accurate methods…
Abstract Number: 352 • 2018 ACR/ARHP Annual Meeting
Polymyalgia Rheumatica-like Syndrome from Checkpoint Inhibitor Therapy: Case Series and Systematic Review of the Literature
Cassandra Calabrese¹, Elizabeth Kirchner¹ and Leonard H. Calabrese², ¹Rheumatic & Immunologic Disease, Cleveland Clinic Foundation, Cleveland, OH, ²Rheumatic & Immunologic Disease and Infectious Disease, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Rheumatic immune related adverse events (irAEs) from checkpoint inhibitor (ICI) therapy remain poorly understood. In our early experience with rheumatic irAEs we encountered patients…
Abstract Number: 116 • 2017 ACR/ARHP Annual Meeting
Immunotherapy-Induced Rheumatic Disease: How Prepared Are Rheumatologists to Address This Emerging Condition?
Laura Cappelli^1,2, Cassandra Calabrese³, Leonard H. Calabrese³ and Clifton O. Bingham III⁴, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Medicine/Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Rheumatic & Immunologic Disease, Cleveland Clinic Foundation, Cleveland, OH, ⁴Rheumatology, Johns Hopkins University, Baltimore, MD
Background/Purpose: Cancer immunotherapy targeting immune checkpoints represents a major advance in oncology, yet has been associated with immune-related adverse events (IRAEs) affecting many organ systems,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].